On February 5, 2020, the Centers for Medicare & Medicaid Services (CMS) released Part II of the Advance Notice of Methodological Changes for Calendar Year (CY) 2021 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, outlining proposed payment changes and other requirements for plan sponsors participating in MA and the Part D program for the upcoming contract year.
On February 5, 2020, the Centers for Medicare & Medicaid Services (CMS) released the CY 2021 and 2022 Medicare Advantage and Medicare Prescription Drug Benefit Program Policy and Technical Rule, outlining proposed programmatic changes to the MA and Part D programs for two upcoming contract years. In a break from historic precedent, many of the program and policy changes that historically had been included in the Draft Call Letter were included in this proposed rule.
This JMCP study compares pay-for-success and pay-for-failure models to identify the short- and long-term incentives for each that manufacturers and payers should consider when developing value-based contracts. More research is needed on the effect of different types of value-based contract schemes on cost and clinical outcomes.
AMCP Submits Comments to HHS OIG on Proposed Revisions to AKS Safe Harbors; AMCP to Comment on White House Proposal to Allow Drug Importation; FDA Issues Draft Guidance on Interchangeable Insulin; AMCP Invited to Participate in Pharmaceutical Quality Workshop